These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Population pharmacokinetic analysis of blood concentrations of robenacoxib in dogs with osteoarthritis. Fink M, Letellier I, Peyrou M, Mochel JP, Jung M, King JN, Gruet P, Giraudel JM. Res Vet Sci; 2013 Oct; 95(2):580-7. PubMed ID: 23726662 [Abstract] [Full Text] [Related]
8. Pharmacokinetic/pharmacodynamic modelling of robenacoxib in a feline tissue cage model of inflammation. Pelligand L, King JN, Toutain PL, Elliott J, Lees P. J Vet Pharmacol Ther; 2012 Feb; 35(1):19-32. PubMed ID: 21767277 [Abstract] [Full Text] [Related]
10. Six-month safety evaluation of robenacoxib tablets (Onsior™) in dogs after daily oral administrations. Toutain CE, Brossard P, King SB, Helbig R. BMC Vet Res; 2018 Aug 17; 14(1):242. PubMed ID: 30119677 [Abstract] [Full Text] [Related]
11. Analgesic and anti-inflammatory actions of robenacoxib in acute joint inflammation in dog. Schmid VB, Spreng DE, Seewald W, Jung M, Lees P, King JN. J Vet Pharmacol Ther; 2010 Apr 17; 33(2):118-31. PubMed ID: 20444036 [Abstract] [Full Text] [Related]
13. Safety of oral robenacoxib in the cat. King JN, Hotz R, Reagan EL, Roth DR, Seewald W, Lees P. J Vet Pharmacol Ther; 2012 Jun 17; 35(3):290-300. PubMed ID: 21736587 [Abstract] [Full Text] [Related]
14. Safety evaluation of the interchangeable use of robenacoxib in commercially-available tablets and solution for injection in cats. Heit MC, Stallons LJ, Seewald W, Thompson CM, Toutain CE, King SB, Helbig R. BMC Vet Res; 2020 Sep 25; 16(1):355. PubMed ID: 32988403 [Abstract] [Full Text] [Related]
15. Influence of sevoflurane anesthesia with mechanical ventilation and fluid-therapy on distribution of subcutaneously administered robenacoxib in dogs. Oyama N, Sano T, Yamamori M, Tamura J, Umar MA, Endo Y, Ishikawa Y, Itoh A, Miyoshi K, Yamashita K. J Vet Med Sci; 2018 Sep 26; 80(9):1450-1455. PubMed ID: 30078791 [Abstract] [Full Text] [Related]
16. Pharmacology, safety, efficacy and clinical uses of the COX-2 inhibitor robenacoxib. Lees P, Toutain PL, Elliott J, Giraudel JM, Pelligand L, King JN. J Vet Pharmacol Ther; 2022 Jul 26; 45(4):325-351. PubMed ID: 35460083 [Abstract] [Full Text] [Related]
17. Effects of route of administration and feeding schedule on pharmacokinetics of robenacoxib in cats. King JN, Jung M, Maurer MP, Schmid VB, Seewald W, Lees P. Am J Vet Res; 2013 Mar 26; 74(3):465-72. PubMed ID: 23438125 [Abstract] [Full Text] [Related]
19. Robenacoxib vs. carprofen for the treatment of canine osteoarthritis; a randomized, noninferiority clinical trial. Reymond N, Speranza C, Gruet P, Seewald W, King JN. J Vet Pharmacol Ther; 2012 Apr 26; 35(2):175-83. PubMed ID: 21480932 [Abstract] [Full Text] [Related]
20. Examination of the pharmacokinetics and differential inhibition of cyclooxygenase isoenzymes in New Zealand white rabbits (Oryctolagus cuniculus) by the Non-Steroidal anti-inflammatory Robenacoxib. Jeffrey A, Gardhouse S, Kleinhenz M, Hocker SE, Weeder M, Montgomery SR, Zhang Y, Porting A, Rooney T. J Vet Pharmacol Ther; 2023 Mar 26; 46(2):103-111. PubMed ID: 36478376 [Abstract] [Full Text] [Related] Page: [Next] [New Search]